Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.08M | $10.1M | $13.5M | $21.0M | $2.82M | $10.3M |
| Revenue growth | — | 834.7% | 33.5% | 55.5% | -86.6% | 266.7% |
| Operating income | -$26.2M | -$48.6M | -$66.6M | -$93.5M | -$135M | -$136M |
| Operating margin | -2417.8% | -479.6% | -492.3% | -444.0% | -4787.7% | -1315.4% |
| Net income | -$26.1M | -$48.6M | -$66.2M | -$89.2M | -$127M | -$130M |
| Net margin | -2408.0% | -479.5% | -489.3% | -423.9% | -4527.7% | -1256.8% |
| EPS (diluted) | -$28.52 | -$4.17 | -$2.75 | -$1.36 | -$1.14 | -$1.00 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.02M | -$48.7M | -$66.5M | -$61.4M | -$111M | -$135M |
| Capital expenditures | $4.24M | $9.94M | $4.22M | $3.15M | $3.83M | $4.41M |
| Free cash flow | -$7.26M | -$58.6M | -$70.7M | -$64.5M | -$115M | -$140M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.8M | $161M | $120M | $133M | $179M | $152M |
| Total assets | $49.7M | $188M | $199M | $272M | $371M | $229M |
| Total liabilities | $32.5M | $27.3M | $99.7M | $121M | $130M | $106M |
| Long-term debt | — | — | $29.3M | $26.7M | $32.1M | $32.5M |
| Shareholders' equity | -$42.5M | $161M | $99.4M | $151M | $241M | $123M |
| Retained earnings | -$43.5M | -$92.2M | -$158M | -$248M | -$375M | -$505M |
| Shares (wtd avg diluted) | — | 11.7M | 24.0M | 65.6M | 112M | 130M |
Every figure is extracted from TScan Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.